Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Stock Short Interest Report for October

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totaling 23,906 shares, a drop of 73.4% from the September 30th total of 89,977 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average trading volume of 49,073 shares, the days-to-cover ratio is presently 0.5 days.

Global X Genomics & Biotechnology ETF Stock Performance

Global X Genomics & Biotechnology ETF stock traded down $3.52 during midday trading on Friday, hitting $69.02. 17,994 shares of the company’s stock were exchanged, compared to its average volume of 21,119. The stock has a 50-day moving average price of $66.81 and a two-hundred day moving average price of $53.66. Global X Genomics & Biotechnology ETF has a 52-week low of $41.16 and a 52-week high of $74.19. The company has a market cap of $109.73 million, a P/E ratio of -29.49 and a beta of 1.17.

Institutional Investors Weigh In On Global X Genomics & Biotechnology ETF

Large investors have recently bought and sold shares of the business. SBI Securities Co. Ltd. raised its position in Global X Genomics & Biotechnology ETF by 36.4% in the third quarter. SBI Securities Co. Ltd. now owns 888 shares of the company’s stock worth $63,000 after acquiring an additional 237 shares during the period. Halbert Hargrove Global Advisors LLC purchased a new position in Global X Genomics & Biotechnology ETF during the third quarter valued at $77,000. Farther Finance Advisors LLC purchased a new position in Global X Genomics & Biotechnology ETF during the third quarter valued at $257,000. Wealth Management Partners LLC grew its holdings in Global X Genomics & Biotechnology ETF by 143.3% during the third quarter. Wealth Management Partners LLC now owns 24,677 shares of the company’s stock valued at $1,739,000 after purchasing an additional 14,533 shares during the period. Finally, Polaris Financial Partners bought a new stake in Global X Genomics & Biotechnology ETF during the third quarter valued at about $1,067,000. 56.95% of the stock is currently owned by institutional investors.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.